Consensus Teva Pharmaceutical Industries Limited TEL AVIV STOCK EXCHANGE

Equities

TEVA

IL0006290147

Market Closed - TEL AVIV STOCK EXCHANGE Other stock markets 10:24:24 2024-04-18 am EDT			5-day change	1st Jan Change
4,978 ^ILa	+0.57%		-4.47%	+30.48%

04:56pm	Alvotech Shares Rise After Signing Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	MT
02:27pm	Alvotech Signs Agreement to Expand Access to Humira Biosimilar Adalimumab-ryvk in US	MT

Evolution of the average Target Price on Teva Pharmaceutical Industries Limited

Price target over the last 5 years

History of analyst recommendation changes

dd6d3b9cb1924411a70c5ac6b01.mu-FeVz3mhGMxICp7o2C7H1jIilNvjG6ltC0vPJ-_f8.z4vHPC6N1mv9obDhtvvthg0HVnwd0USJ5I__xaU6u5ncoOsxE7ajfselxQ~278b0c2a43a539aa271810a37bda64fb

Analyst Recommendations on Teva Pharmaceutical Industries Limited

JPMorgan Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Adjusts Price Target to $14 From $11	Mar. 08	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Overweight From Neutral, Adjusts PT to $19 From $12	Feb. 12	MT
Goldman Sachs Adjusts Price Target on Teva Pharmaceutical Industries to $11 From $10, Maintains Neutral Rating	Feb. 05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $17 From $15, Maintains Overweight Rating	Feb. 05	MT
Barclays Adjusts Price Target on Teva Pharmaceutical Industries to $15 From $14, Maintains Overweight Rating	Jan. 29	MT
Teva: share price up, broker in support	Jan. 23	CF
TEVA : Jefferies raises its recommendation	Jan. 23	CF
Jefferies Upgrades Teva Pharmaceutical Industries to Buy From Hold, Raises Price Target to $14 From $10	Jan. 23	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Buy Rating	Jan. 12	MT
Piper Sandler Upgrades Teva Pharmaceutical Industries to Neutral From Underweight, Raises Price Target to $12 From $8	Jan. 03	MT
HSBC Initiates Teva Pharmaceutical Industries at Buy Rating With $13 Price Target	Dec. 18	MT
UBS Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $11	Nov. 27	MT
UBS Upgrades Teva Pharmaceutical Industries to Neutral From Sell, Raises Price Target to $8 From $7	23-07-06	MT
Evercore ISI Upgrades Teva Pharmaceutical Industries to Outperform From In-Line	23-05-18	MT
Barclays Adjusts Teva Pharmaceutical Industries Price Target to $14 From $13, Maintains Overweight Rating	23-02-09	MT
Jefferies Downgrades Teva Pharmaceutical Industries to Hold From Buy, Adjusts Price Target to $12 From $10	23-01-19	MT
UBS Downgrades Teva Pharmaceutical Industries to Sell From Neutral, Adjusts Price Target to $7 From $10	22-11-04	MT
Jefferies Assumes Teva Pharmaceutical Industries at Buy with $10 Price Target	22-10-21	MT
BofA Securities Adjusts Teva Pharmaceutical Industries Price Target to $11 From $13, Maintains Buy Rating	22-10-14	MT
BofA Securities Upgrades Teva Pharmaceutical Industries to Buy From Neutral, Adjusts Price Target to $13 From $10	22-08-05	MT
ANALYST RECOMMENDATIONS : AMD, CarMax, Gilead, J.B. Hunt, Vodafone...	22-05-17
BofA Securities Upgrades Teva Pharmaceutical Industries to Neutral From Underperform; Price Target is $9	22-05-17	MT
Piper Sandler Downgrades Teva Pharmaceutical Industries to Underweight From Neutral, Adjusts Price Target to $7 From $11	22-05-04	MT
Barclays Lifts Teva Pharmaceutical Industries to Overweight From Equalweight, Price Target to $13 From $11	22-04-05	MT
Bernstein Upgrades Teva Pharmaceutical Industries to Outperform From Market Perform; Price Target is $11	22-03-25	MT